NasdaqGS:IBRXBiotechs
FDA Warning On Anktiva Puts ImmunityBio Growth Story Under Scrutiny
The U.S. FDA has issued a warning letter to ImmunityBio over allegedly false and misleading promotional claims for its bladder cancer drug Anktiva.
The letter focuses on how Anktiva has been marketed to healthcare professionals and patients, and requests corrective action from the company.
This regulatory action introduces additional marketing and compliance risk for ImmunityBio at a time when its drug portfolio is gaining wider attention.
For investors following ImmunityBio, ticker...